Literature DB >> 1450296

Preliminary studies of 6 beta-hydroxydexamethasone and its importance in the DST.

J C Ritchie1, M J Owens, H Mayer, J T Watson, C Kilts, B J Carroll.   

Abstract

The role of the metabolites of dexamethasone (DEX) in the dexamethasone suppression test (DST) has never been fully elucidated. We report here our preliminary studies of 6 beta-hydroxydexamethasone (6 OH-Dex), a known metabolite of DEX, on the hypothalamic-pituitary-adrenal (HPA) axis of the rat; its activity in the most commonly used radioimmunoassay for plasma DEX; and its plasma concentrations in a normal human subject during the standard 1.0 mg DST. Six OH-Dex administered subcutaneously to rats at a dose of 1 mg/kg was able to completely suppress corticosterone production for at least 3 hr. In the IgG Corp. radioimmunoassay for plasma DEX, 6 OH-Dex was moderately cross-reactive yielding a 50% cross-reactivity of 10%. Gas chromatographic coupled mass spectroscopic analysis of human plasma samples, obtained 12 to 20 hr after the oral ingestion of 1.0 mg DEX, demonstrated similar plasma concentrations for both the parent compound and the 6-hydroxyl metabolite. The relevance of these findings, particularly to pharmacokinetic studies of the DST, is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1450296     DOI: 10.1016/0006-3223(92)90086-f

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  2 in total

1.  Antenatal dexamethasone treatment transiently alters diastolic function in the mouse fetal heart.

Authors:  E J Agnew; A Garcia-Burgos; R V Richardson; H Manos; A J W Thomson; K Sooy; G Just; N Z M Homer; C M Moran; P J Brunton; G A Gray; K E Chapman
Journal:  J Endocrinol       Date:  2019-06-01       Impact factor: 4.286

2.  Association between posttest dexamethasone and cortisol concentrations in the 1 mg overnight dexamethasone suppression test.

Authors:  Bjørn O Asvold; Valdemar Grill; Ketil Thorstensen; Marit R Bjørgaas
Journal:  Endocr Connect       Date:  2012-08-30       Impact factor: 3.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.